Target intelligence / Profile preview

Ornithine decarboxylase antizyme 3 (OAZ3)

Target
OAZ3
Molecular classification
Other (Antizyme family, polyamine regulator, testis-specific protein)
01

Overview

**Ornithine decarboxylase antizyme 3 (OAZ3)** is a member of the antizyme family, proteins known to regulate ornithine decarboxylase (ODC) and thus polyamine biosynthesis[1][3][6]. OAZ3 expression is highly specific to haploid germ cells in the testis, where it is essential for spermatogenesis and for the structural coupling of sperm head and tail[1][2][8]. Unlike OAZ1 and OAZ2, OAZ3 does not efficiently promote ODC degradation, and its primary protein product in sperm is a 12 kDa protein (p12) that lacks the canonical antizyme-ODC interaction domain[2][8]. This protein interacts with myosin phosphatase targeting subunit 3 (MYPT3) and modulates protein phosphatase activity relevant to sperm structure[2][8]. Knockout of the OAZ3 gene in mice causes male infertility due to detachment of sperm heads and tails, confirming its specialized role in sperm morphology[1][2][8]. There are currently no drugs known to directly target OAZ3, and it is not considered a classical therapeutic target. Its unique, testis-specific function makes it biologically interesting but limits its relevance for drug therapy outside reproductive medicine.

Other names
AZ3ODC-Az 3OAZ-tTISP15antizyme 3testicular secretory protein Li 31
02

Biological functions

Regulation of intracellular polyamine biosynthesis and uptakeSpermatogenesis, specifically spermiogenesis and head-tail coupling in spermNegative regulator of ornithine decarboxylase activity (inferred from homologous family function, but not primary in OAZ3)Interacts with myosin phosphatase targeting subunit 3 (MYPT3) and modulates protein phosphatase activity (PP1β/PP1γ2)
03

Disease associations

Male infertility (defective head-tail coupling in sperm)Other (no evidence for major roles in cancer, neurodegeneration, or other common pathologies)
04

Safety considerations

No drugs developed against OAZ3; testis-restricted expression suggests low off-target risk, but targeting may impair spermatogenesis/fertility
05

Biomarkers

OAZ3 expression is a marker of post-meiotic male germ cells in testis, but not used clinically as a biomarker

Beyond the preview

Go deeper on Ornithine decarboxylase antizyme 3 (OAZ3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ornithine decarboxylase antizyme 3 (OAZ3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call